新検索ページはこちら
ログイン
お問い合わせ
（旧版）前立腺癌診療ガイドライン 2006年版
書誌情報
第3章 治療総論
参考文献
4 放射線療法 ＊この項の文献番号は、「第5章放射線療法」の文献番号と対応しています。
| 1） | Zietman AL, Chung CS, Coen JJ, et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy:results of a cohort study. J Urol. 2004;171:210-4. |
| 2） | Pilepich MV, Krall JM, John MJ, et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy:preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys. 1989;16:813-7. |
| 3） | Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy:report of RTOG 85-31. J Clin Oncol. 1997;15:1013-21. |
| 4） | Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long term results of phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-90. |
| 5） | Lawton CA, Winter K, Murray K, et al. Updated results of the phase III RTOG trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-46. |
| 6） | Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300. |
| 7） | Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer（an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-6. |
| 8） | Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma:a randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 1995;45:616-23. |
| 9） | Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group（RTOG）trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-52. |
| 10） | Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate:the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-8. |
| 11） | Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression:Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904-11. |
| 12） | D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer:a randomized controlled trial. JAMA. 2004;292:821-7. |
| 13） | D'Amico A, Whittington R, Malkowicz S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74. |
| 14） | Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-15. |
| 15） | Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-9. |
| 16） | Pollack A, Zagars GK, Starkschall G, et al. Prostate caner radiation dose response:results of the M. D. Anderson phase III randomized trial. Int Radiat Oncol Biol Phys. 2002;53:1097-105. |
| 17） | Deger S, Boehmer D, Turk I, et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol. 2002;41:420-6. |
| 18） | Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer:preliminary PSA outcome from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297-303. |
| 19） | American Society for Therapeutic Radiology and Oncology Consensus Panel, Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035-41. |
| 20） | Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553-61. |
| 21） | Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:1212-9. |
| 22） | Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure:analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54:677-85. |
